This is a working overview of lyophilization, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-31 and is reviewed periodically as new material appears.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.
Routine characterisation of the peptide relies on reversed-phase high-performance liquid chromatography, often paired with ultraviolet detection near 214 nanometres. Related substances such as deamidated, oxidised, and truncated sequences elute at characteristic positions and are quantified by area percentage. Electrospray ionisation mass spectrometry confirms the molecular mass and can resolve some closely related variants. Peptide mapping after enzymatic digestion provides sequence-level verification and is useful when a full identity profile is required. Method parameters such as column chemistry, gradient, and mobile-phase pH influence the separation and must be reported alongside results.
Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Water and aqueous buffers | Near neutral pH |
| Storage temperature | Minus 20 to minus 80 C | Long-term, lyophilized |
| Analytical method | RP-HPLC | Purity assessment |
| Typical purity | Greater than 95 percent | Research-grade material |
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
=== Discontinued === ABT-436 – vasopressin V1b receptor antagonist – alcoholism Adrogolide (ABT-431; DAS-431) – dopamine D1 receptor agonist – cocaine-related disorders ADX-629 – aldehyde inhibitor / reactive aldehyde species (RASP) inhibitor – alcoholism, alcoholic hepatitis ADX-10061 (CEE-310; CEE-03-310; NNC-010687; NNC-687) – dopamine D1 receptor antagonist – smoking withdrawal, substance-related disorders ADX-71441 – GABAB receptor positive allosteric modulator – alcoholism, cocaine-related disorders, substance-related disorders Anatabine (RCP-006) – nicotinic acetylcholine receptor agonist – smoking withdrawal ANS-6637 (GS-6637; GS-6673) – aldehyde dehydrogenase 2 (ALDH2) inhibitor – alcoholism, opioid-related disorders, smoking withdrawal, substance-related disorders Arbaclofen placarbil (R-baclofen placarbil; XP-19986) – GABAB receptor agonist – alcoholism ASP-8062 – GABAB receptor modulator – opioid-related disorders Aticaprant (AVTX-501; CERC-501; JNJ-3964; JNJ-67953964; JNJ-67953964-AAA; LY-2456302) – κ-opioid receptor antagonist – alcoholism, cocaine-related disorders, smoking withdrawal Azasetron (nazasetron; Serotone; Y-25130) – serotonin 5-HT3 receptor antagonist – cocaine-related disorders AZD-4041 – orexin OX1 receptor antagonist – smoking withdrawal Baclofen/samidorphan (ALKS-29; ALKS-33/baclofen; baclofen/ALKS-33) – combination of baclofen (GABAB receptor agonist) and samidorphan (μ-opioid receptor antagonist) – alcoholism Befloxatone (MD-370503) – monoamine oxidase A (MAO-A) inhibitor – smoking withdrawal BP-897 – dopamine D3 receptor agonist – cocaine-related disorders BR-9003 (BR-9003A) – undefined mechanism of action – smoking withdrawal BTRX-246040 (LY-2940094) – nociceptin receptor agonist – alcoholism Buprenorphine/naloxone (NanoBUP; NTC-0510; NTC-510) – combination of buprenorphine (non-selective opioid receptor modulator) and naloxone (orally/sublingually inactive opioid receptor antagonist) – opioid-related disorders Buprenorphine/samidorphan (ALKS 33-BUP; ALKS 33/buprenorphine; ALKS-5461; BUP-ALKS 33; buprenorphine/ALKS-33; buprenorphine/RDC 0313; RDC 0313/buprenorphine; samidorphan/buprenorphine) – combination of buprenorphine (non-selective opioid receptor modulator) and samidorphan (μ-opioid receptor antagonist) – cocaine-related disorders Cannabidiol (CBD; synthetic cannabidiol; RAD-011) – cannabinoid/various actions – substance-related disorders CVL-936 – dopamine D2 and D3 receptor antagonist – substance-related disorders CX-1739 – AMPA receptor positive allosteric modulator (ampakine) – substance-related disorders Deudimethyltryptamine (HLP004; HLP-004; CYB004; CYB-004; DMT-d10; deuterated dimethyltryptamine; dDMT) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, and serotonergic psychedelic – substance-related disorders Deupsilocin (HLP003; HLP-003; CYB003; CYB-003; psilocin-d10; deuterated psilocin) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, and serotonergic psychedelic – alcoholism Dianicline (SSR-591813) – nicotinic acetylcholine receptor agonist – smoking withdrawal Drinabant (AVE-1625; INDV-5004; OPNT-004) – cannabinoid CB1 receptor antagonist – substance-related disorders Ecopipam (EBS-101; PSYRX-101; SCH-39166) – dopamine D1 receptor antagonist – cocaine-related disorders Eglumetad (eglumegad; LY-354740) – metabotropic glutamate mGlu2 and mGlu3 receptor agonist – smoking withdrawal Elinzanetant (BAY-3427080; GSK-1144814A; GSK-1144814; Lynkuet; NT-814) – neurokinin NK1 and NK3 receptor antagonist – opioid-related disorders Femoxetine (femoxitine; FG-4963; Malexil; NNC-204963) – selective serotonin reuptake inhibitor (SSRI) – alcoholism Gabapentin enacarbil (ASP8825; Gabapentin-XP; GSK-1838262; Horizant; Regnite; Solzira; XP13512) – gabapentinoid (α2δ subunit-containing voltage-gated calcium channel blocker) – alcoholism Gepirone (Ariza; BMY-13805; Exxua; MJ-13805; Org-33062; TGFK07AD; Travivo; Variza) – serotonin 5-HT1A receptor agonist – cocaine-related disorders Istradefylline (KW-6002; Nourianz; Nouriast) – adenosine A2 receptor antagonist ITI-333 – serotonin 5-HT2A receptor antagonist, dopamine D1 receptor antagonist, α1A-adrenergic receptor antagonist, μ-opioid receptor partial agonist – substance-related disorders JNJ-39393406 – α7 subunit-containing nicotinic acetylcholine receptor positive allosteric modulator – smoking withdrawal JZP-150 – fatty acid amide hydrolase (FAAH) inhibitor – alcoholism Lisdexamfetamine (LDX; Elvanse; NRP-104; S-877489; SHP-489; SPD-489; Tyvense; Venvanse; Vyvanse) – norepinephrine–dopamine releasing agent (NDRA) – cocaine-related disorders Lorcaserin (APD-356; Belviq; E2023; Venespri) – serotonin 5-HT2C receptor agonist – smoking withdrawal Manifaxine (BW-1555U88; GW-320659) – norepinephrine–dopamine reuptake inhibitor (NDRI) – smoking withdrawal Mavoglurant (AFQ-056; STP-7) – metabotropic glutamate mGlu5 receptor antagonist – smoking withdrawal Nalmefene (CPH-101; JF-1; Lu AA36143; Nalmetrene; NIH-10365; ORF-11676; Selincro; Soberal) – μ-opioid receptor antagonist, κ-opioid receptor weak partial agonist – smoking withdrawal Nepicastat oral (APL-1401; SYN-117) – dopamine β-hydroxylase (DBH) inhibitor – cocaine-related disorders Neramexane (KRP-209; MRZ-2/579) – NMDA receptor antagonist, nicotinic acetylcholine receptor antagonist – alcoholism NIC-002 (NIC002; CYT002-NicQβ; Nicotine-Qβ) – immunostimulant (nicotine vaccine) – smoking withdrawal NicVAX – immunostimulant (nicotine vaccine) – smoking withdrawal Nornicotine – nicotinic acetylcholine receptor agonist – smoking withdrawal NS-2359 (GSK-372475) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) – alcoholism NYX-783 – ionotropic glutamate NMDA receptor modulator – alcoholism, opioid-related disorders OREX-1019 – μ-opioid receptor agonist, δ-opioid receptor antagonist, κ-opioid receptor antagonist, nociceptin receptor agonist – cocaine-related disorders OREX-1038 – μ-opioid receptor agonist – cocaine-related disorders, opioid-related disorders Oxytocin intranasal (Syntocinon Nasal Spray; TUR-001) – oxytocin receptor agonist – alcoholism Quetiapine (FK-949; FK949E; ICI-204636; Seroquel) – atypical antipsychotic (non-selective monoamine receptor modulator) – alcoholism Rimonabant (Acomplia; SR-141716; SR-141716A; Zimulti) – cannabinoid CB1 receptor antagonist – smoking withdrawal Risperidone (JNJ-410397-AAA; R-64766; R064766; Risperdal; Risperdal Consta; Risperdal Depot) – atypical antipsychotic (non-selective monoamine receptor modulator) – substance-related disorders RTI-113 – dopamine reuptake inhibitor (DRI) (cocaine analogue) – cocaine-related disorders Samidorphan (ALKS-33; RDC-0313; RDC-0313-00) – μ-opioid receptor antagonist – alcoholism, substance-related disorders Sembragiline (EVT-302; RG-1577; RO-4602522) – monoamine oxidase B (MAO-B) inhibitor – smoking withdrawal Serlopitant (JTS-661; MK-0594; VPD-737) – neurokinin NK1 receptor antagonist – alcoholism Surinabant (SR-147778; SR147778) – cannabinoid CB1 receptor antagonist – alcoholism, smoking withdrawal TA-NIC – immunostimulant (nicotine vaccine) – smoking withdrawal Tradipitant (LY-686017; Nereus; VLY-686) – neurokinin NK1 receptor antagonist – alcoholism Verucerfont (GSK-561679; NBI-77860) – corticotropin-releasing factor 1 (CRF1) receptor antagonist Vigabatrin (γ-vinyl-GABA; gamma-vinyl-GABA; GVG; M071754; MDL-71754; RMI-71754; Sabril; Sabrilex) – GABA transaminase (GABA-T) inhibitor – cocaine-related disorders, substance-related disorders
Amat-Mamu (fl. c. 1736 BC) was a Babylonian nadītu priestess in Sippar from the 18th century BC who was the subject of legal proceedings involving her inheritance. Amat-Mamu was chosen as the heir of fellow nadītu Belessunu, who bequeathed Amat-Mamu her land and slaves. In exchange, Amat-Mamu was to provide for Belessunu until her death. The estate was claimed by two of Belessunu's cousins, but the mayor ruled in favor of Belessunu and Amat-Mamu. Amat-Mamu then lost the deeds when they were kept in her uncle's home, requiring her to have them reconstituted in a new tablet. This tablet was preserved, and its description of Amat-Mamu's inheritance provides insight into Babylonian inheritance practices.
B1007 provides a road link to Basildon, via the A127; it passes from just south of the town centre as Laindon Road, then Sun Corner, and northwards as Billericay's High Street and Stock Road. The road continues north to Chelmsford, via the village of Stock and an interchange to the A12 A129 provides an east-west link between Hadleigh, Wickford and Shenfield.
Sources: en.wikipedia.org
=== Public awareness === Public awareness of the disease, which is spread through the exchange of bodily fluids, is not as high as it is for HIV and AIDS. In some rural areas, doctors have reused syringes and unknowingly spread the disease, particularly among children.
== History == The oxymetazoline brand Afrin was first sold as a prescription medication in 1966. After finding substantial early success as a prescription medication, it became available as an over-the-counter drug in 1975. Schering-Plough did not engage in heavy advertising until 1986.
Codex Alimentarius Codex Alimentarius General Standard for Irradiated Foods (CAC/STAN 106-1983, rev.1 2003) at the Wayback Machine (archived 2007-09-26) Codex Alimentarius Recommended International Code of Practice Code for Radiation Processing of Foods (CAC/RCP 19-1979, rev.2 – 2003) Archived October 5, 2021, at the Wayback Machine General Standard for the Labelling of Prepacked Foods (CODEX STAN 1-1985) Archived April 6, 2011, at the Wayback Machine Food Irradiation Processing Alliance FIPA represents the irradiation service industry, manufacturers of food irradiators and suppliers of cobalt-60 sources. Irradiation of Food and Food Packaging at the Wayback Machine (archived 2009-03-04), Center for Food Safety and Applied Nutrition (US Government) Facts about Food Irradiation at the Wayback Machine (archived 2006-03-16), a series of 14 fact sheets, International Consultative Group on Food Irradiation, International Atomic Energy Agency, Vienna, 1991 Bibliography on Food Irradiation Archived May 3, 2006, at the Wayback Machine, Federal Research Centre for Nutrition and Food, Karlsruhe, Germany IAEA interactive map of irradiation facilities Archived April 20, 2021, at the Wayback Machine Keener, Kevin M. "Department of Food Science Food Irradiation: To Zap or not to Zap?" (PDF). North Carolina State University. Archived from the original (PDF) on September 7, 2015. Retrieved January 12, 2021.
Charlemagne founded the Carolingian Empire in 800; it was divided in 843. The eastern successor kingdom of East Francia stretched from the Rhine in the west to the Elbe river in the east and from the North Sea to the Alps. Subsequently, the Kingdom of Germany and the Holy Roman Empire emerged from it. The Ottonian rulers (919–1024) consolidated several major duchies. In 996, Gregory V became the first German Pope, appointed by his cousin Otto III, whom he shortly after crowned Holy Roman Emperor. The Holy Roman Empire absorbed northern Italy and Burgundy under the Salian emperors (1024–1125), although the emperors lost power through the Investiture Controversy. Under the Hohenstaufen emperors (1138–1254), German princes encouraged German settlement to the south and east (Ostsiedlung). Members of the Hanseatic League, mostly north German towns, prospered in the expansion of trade. The population declined starting with the Great Famine in 1315, followed by the Black Death of 1348–1350. The Golden Bull issued in 1356 provided the constitutional structure of the Empire and codified the election of the emperor by seven prince-electors. Johannes Gutenberg introduced moveable-type printing to Europe, laying the basis for the democratisation of knowledge. Following Martin Luther's 1517 Protestant Reformation, bolstered by his standardised Bible translation, led to the 1555 Peace of Augsburg, which recognised Lutheranism under the principle of cuius regio, eius religio (ruler's faith dictates subjects' faith).
Sources: en.wikipedia.org
==== Solid support material ==== In contrast to organic solid-phase synthesis and peptide synthesis, the synthesis of oligonucleotides proceeds best on non-swellable or low-swellable solid supports. The two most often used solid-phase materials are controlled pore glass (CPG) and macroporous polystyrene (MPPS).
==== Elimination ==== The elimination half-life of sertraline is on average 26 hours, with a range of 13 to 45 hours. The elimination half-life of desmethylsertraline is 62 to 104 hours. In a small study of two people, sertraline was excreted to similar degrees in urine and feces (40 to 45% each within 9 days). Unchanged sertraline was not detectable in urine, whereas 12 to 14% of unchanged sertraline was present in feces.
Pegylated interferon alfa-2b is a drug used to treat melanoma, as an adjuvant therapy to surgery. Also used to treat hepatitis C (typically, in combination with ribavirin), it is no longer recommended due to poor efficacy and adverse side-effects. Subcutaneous injection is the preferred delivery method. Belonging to the alpha interferon family of medications, the molecule is PEGylated to prevent breakdown. Approval for medical use in the United States was granted in 2001. It is on the World Health Organization's List of Essential Medicines as a therapy for chronic hepatitis C.
Establishment of antimicrobial programs within acute care hospital settings Reduction of inappropriate antibiotic prescription and use by at least 50% in outpatient settings and 20% inpatient settings Establishment of State Antibiotic Resistance (AR) Prevention Programs in all 50 states Elimination of the use of medically important antibiotics for growth promotion in food-producing animals. Current Status of AMR in the U.S. As of 2023, AMR remains a public health threat in the United States. According to the Centers for Disease Control and Prevention's 2023 Report on Antibiotic Resistance Threats, over 2.8 million antibiotic-resistant infections occur in the U.S. each year, leading to at least 35,000 deaths annually. Among the most concerning resistant pathogens are Carbapenem-resistant Enterobacteriaceae (CRE), Methicillin-resistant Staphylococcus aureus (MRSA), and Clostridioides difficile (C. diff), all of which continue to be responsible for severe healthcare-associated infections (HAIs). The COVID-19 pandemic led to a disruption in healthcare, with an increase in the use of antibiotics during the treatment of viral infections. This rise in antibiotic prescribing, coupled with overwhelmed healthcare systems, contributed to a resurgence in AMR during the pandemic years. A 2021 CDC report identified a sharp increase in HAIs caused by resistant pathogens in COVID-19 patients, a trend that has persisted into 2023. Recent data suggest that although antibiotic use has decreased since the pandemic, some resistant pathogens remain prevalent in healthcare settings.
=== Emergency medicine === He accepted a position as director of an emergency room at the University of Virginia, where he made several advances in emergency care: an emergency medical communication system for ambulances, emergency training for ambulance attendants, a rape crisis center, a crisis center for the deaf, a poison control center, an advanced life support emergency medical system, and the first medical air transport system in the Commonwealth of Virginia. Edlich was one of eight physician technical advisors for the Department of Emergency Medical Services of the US Department of Health Education and Welfare to develop emergency medical systems throughout the US. He supervised the development of emergency medical systems in the Virginia, Pennsylvania, West Virginia, Maryland, Washington DC, and Puerto Rico. In 1979, Edlich received the Distinguished Public Service Award for Contributions to Emergency Medicine by the US Public Health Service.
Sources: en.wikipedia.org
Long-term storage is usually at minus 20 to minus 80 degrees Celsius in a sealed, desiccated container. Working aliquots can be held briefly at 2 to 8 degrees Celsius.
Repeated temperature cycling can promote aggregation and peptide degradation. Dividing material into single-use aliquots limits this risk.
Mass spectrometry is commonly used to confirm molecular mass and detect structural modifications. It is often paired with chromatographic purity assessment.
Different techniques detect different classes of impurities, so a single number does not describe a sample completely. Reversed-phase chromatography resolves related peptides well but can miss inorganic salts, while mass spectrometry confirms mass without quantifying everything present. Comparing results requires knowing which method was used and how it was validated.